Hi Km, Malcolm posted an article on twitter Focus on Oncology. I...

First 17 Last

Share
Profile

Follow
Lopez

12,359 Posts.

1105

25/10/17

10:54

Post #: 28174515
Share

Originally posted by kmsmith ↑

Morning all,
I could not agree more that owning VLA shares has been a real test of patience. There are so many things I do not understand. If we owned technology that meant a car could drive twice the distance on a tank of petrol, I imagine we could sell it to one of the car manufacturers in about 8 minutes. VLA have a product that seems to mean the effectiveness of other products is increased just as much. In something so much more important than fuel efficiency. Yet the result is …. we do some more trials.

In a sense it is hard to blame Management because, with podium presentations, VLA just must be on the radar of more than one large pharma. They cannot force them to make offers. Why they would not be clamouring at the door (and already make significant offers) is mystifying.

The one positive I can take from recent releases is the comment that they are ‘Planning now for a pivotal trial’. I assume this is saying that if absolutely necessary we will try for a Phase 3 trial ourselves. NEU have done similar by targeting a gut-wrenching conditions known as Retts. As the numbers are small numbers for a Phase 3 are much smaller than most Phase 3 trials. At one stage I seem to recall VLA talking about trials aimed at those patients who had failed Keytruda etc. I wonder if we get a much smaller target might mean we can have a smaller Phase 3 trial? I am no expert though. Any more knowledgeable posts would be appreciated.

Either way, with Health funds now on the register who can all see the potential, you would think Phase 3 must be a possibility. How good would that be? Probably water down holdings significantly, but if then we get a much higher % of Sales it would still be a great outcome.

In previous years, I have made it to the AGM (10 years+ I would think) and posted a summary of proceedings. This year I will be away so hopefully someone else (Bripoz, believe you said you were going??) can give a summary this year.

Trust you all have a magnificent day!

Rgds
KMS

Expand

Hi Km,
Malcolm posted an article on twitter Focus on Oncology.
I think that sums up his game plan.
The more convincing the Data the larger the deal.
To my mind it's getting very close.
If the share price was $2 i doubt the board would be so disgruntled.
Also interesting that in the latest report Malcolm went out of his way to tell us a few of our competitors have fallen by the wayside.
By the way VLA have a line of communication so if you have a beef email them.
Aloha.

VLA Price at posting: 81.0¢ Sentiment: Buy Disclosure: Held
4 Upvote

0 Great analysis

Reply

Top Stories

NTI

Neurotech knocked back by FDA as agency declares target condition not rare enough for special status

BUX

Buxton projects new graphite province discovery at WA Narryer play

Week 40 Wrap: China's nonsensical stimmy hype wanes (shocking!); HotCopper's picks; oil & inflation

BCI

BCI reaches close of funding facility for salt-first part of Mardie project

COD

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

WCN

White Cliff jumps 24% on 'bonanza grade' copper rock chips at Rae project, Canada

SLS

Solstice Minerals to ramp up drilling campaign at Yarri Gold Project

ACW

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

RCE

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

CKA

Cokal upgrades infrastructure for BBM ramp-up in Indonesia

There are more pages in this discussion • 9 more messages in this thread...

First 17 Last

Add VLA (ASX) to my watchlist

Hi Km, Malcolm posted an article on twitter Focus on Oncology. I...

Top Stories

Neurotech knocked back by FDA as agency declares target condition not rare enough for special status

Buxton projects new graphite province discovery at WA Narryer play

Week 40 Wrap: China's nonsensical stimmy hype wanes (shocking!); HotCopper's picks; oil & inflation

BCI reaches close of funding facility for salt-first part of Mardie project

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

White Cliff jumps 24% on 'bonanza grade' copper rock chips at Rae project, Canada

Solstice Minerals to ramp up drilling campaign at Yarri Gold Project

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Cokal upgrades infrastructure for BBM ramp-up in Indonesia

Featured News